Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Systematic Reviews and Meta-Analyses of Genitourinary Cancers (2nd Edition)
share announcement

Systematic Reviews and Meta-Analyses of Genitourinary Cancers (2nd Edition)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Systematic Review or Meta-Analysis in Cancer Research".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 1206

Special Issue Editors

Prof. Dr. Giorgio Treglia

E-Mail Website
Guest Editor
Division of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland
Interests: PET; nuclear medicine; hybrid imaging; meta-analysis
Special Issues, Collections and Topics in MDPI journals
Dr. Ursula Maria Vogl

E-Mail Website
Guest Editor
Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland
Interests: genitourinary oncology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Systematic reviews and meta-analyses are evidence-based articles representing the highest level of evidence in the scientific literature. As such, they are increasingly used in oncology, providing useful information for decision making.

Genitourinary oncology is a specialized field focused on the diagnosis and treatment of cancers found in the urinary and male reproductive systems, including prostate, kidney, bladder, testicular, and penile cancers.

According to data in the literature, the use of systematic reviews and meta-analyses in genitourinary oncology is increasing.

We are pleased to invite you to contribute to this Special Issue of Cancers, dedicated to evidence-based manuscripts (systematic reviews and/or meta-analyses) in the field of genitourinary oncology, with a special focus on cancer diagnosis and therapy.

We look forward to receiving your contributions

Prof. Dr. Giorgio Treglia
Dr. Ursula Maria Vogl
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • systematic review
  • meta-analysis
  • oncology
  • genitourinary cancers
  • diagnosis
  • therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

14 pages, 600 KiB  
Systematic Review
Active Surveillance in Non-Muscle Invasive Bladder Cancer: A Systematic Review
by Míriam Campistol, Fernando Lozano, Albert Carrion, Carles Xavier Raventós, Juan Morote and Enrique Trilla
Cancers 2025, 17(10), 1714; https://doi.org/10.3390/cancers17101714 - 20 May 2025
Viewed by 449
Abstract
Bladder cancer is the ninth most common cancer globally, with most cases classified as non-muscle-invasive bladder cancer (NMIBC). While transurethral resection of the bladder tumor (TURBT) remains the gold-standard treatment, its complications, high recurrence rates, and economic burden have prompted interest in alternative [...] Read more.
Bladder cancer is the ninth most common cancer globally, with most cases classified as non-muscle-invasive bladder cancer (NMIBC). While transurethral resection of the bladder tumor (TURBT) remains the gold-standard treatment, its complications, high recurrence rates, and economic burden have prompted interest in alternative strategies like active surveillance (AS) for low-grade and low-grade NMBIC recurrences. AS minimizes surgical interventions and patient burden, but lacks standardized protocols for inclusion criteria and follow-up schedules. Most studies suggest intensive monitoring during the first year, with criteria often based on tumor size, number, and grade. Acquisition of evidence: A comprehensive literature search was conducted in December 2024 using Pubmed, Cochrane, and Trip databases to identify studies on AS for low-grade NMBIC recurrences. Only English studies were included, with Boolean operators used to refine the search. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the Population, Intervention, Comparison and Outcomes (PICO) selection criteria were followed. The Newcastle–Ottawa quality assessment scale was used to analyze the quality of the included studies. Evidence synthesis: This systematic review included 11 studies evaluating AS for NMIBC. Early studies, such demonstrated AS as a feasible alternative to TURBT, with low progression rates. Subsequent research confirmed its safety in selected patients, with tumor growth and positive cytology being the main reasons for intervention. More recent investigations, further supported AS as a viable strategy, highlighting the low risk of stage and grade progression and its potential to reduce surgical interventions. Conclusions: AS may be considered an alternative approach for low-risk NMIBC recurrences. However, there is need for prospective studies and personalized approaches to optimize AS, addressing follow-up strategies, inclusion criteria and progression thresholds. Full article
(This article belongs to the Special Issue Systematic Reviews and Meta-Analyses of Genitourinary Cancers (2nd Edition))
►▼ Show Figures

Figure 1

12 pages, 1788 KiB  
Systematic Review
Survival Outcomes Associated with the Location of BRCA Mutations in Ovarian Cancer: A Systematic Review and Meta-Analysis
by Ji Hyun Kim, Hyung Joon Yoon, Hyeong In Ha, Eun Taeg Kim, Dongkyu Eugene Kim, Sangeon Kim, Jae Kyung Bae and Myong Cheol Lim
Cancers 2025, 17(10), 1661; https://doi.org/10.3390/cancers17101661 - 14 May 2025
Viewed by 446
Abstract
Background/Objective: BRCA1 and BRCA2 genes contain functional domains that operate at different stages of the DNA damage response. Although studies have suggested that the location of BRCA1/2 mutations may influence clinical outcomes, no discernible pattern has been observed indicating which mutation location influences [...] Read more.
Background/Objective: BRCA1 and BRCA2 genes contain functional domains that operate at different stages of the DNA damage response. Although studies have suggested that the location of BRCA1/2 mutations may influence clinical outcomes, no discernible pattern has been observed indicating which mutation location influences clinical outcomes in patients with ovarian cancer with BRCA1/2 mutations. Therefore, this study aimed to evaluate the differences in survival outcomes between BRCA1/2 mutation locations, with a specific focus on exon 11, in patients with epithelial ovarian cancer. Methods: A comprehensive literature review was conducted using PubMed, Embase, and Cochrane Library databases, including articles published up to 13 August 2024. Progression-free survival (PFS) and overall survival (OS) were assessed based on the BRCA mutation location, with subgroup analyses focusing on exon 11 mutations in BRCA1 and BRCA2. Statistical heterogeneity was evaluated using the I2 index. Results: Seven studies involving 1535 patients were included. BRCA2 exon 11 mutations demonstrated a significant PFS advantage (HR, 0.586; 95% CI, 0.346–0.994, I2 = 55%), whereas BRCA1 exon 11 mutations had no significant effect on PFS or OS. Conclusions: These findings suggest differential prognostic outcomes based on the BRCA mutation location, highlighting the clinical relevance of BRCA2 exon 11. BRCA2 exon 11 mutations were associated with improved PFS, which underscores the prognostic significance of the BRCA mutation location, particularly exon 11, in ovarian cancer. These findings reinforce the biological relevance of exon 11 by consolidating evidence from multiple studies that suggest potential prognostic implications of mutations within this region. Full article
(This article belongs to the Special Issue Systematic Reviews and Meta-Analyses of Genitourinary Cancers (2nd Edition))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop